1. Introduction {#s0005}
===============

Several lines of evidence link adult psychotic illness with infection and abnormalities in various components of the immune system. Increased prevalence of antibodies to *Toxoplasma gondii* has been reported in schizophrenia ([@bb0260]). Maternal infection ([@bb0055; @bb0035; @bb0050; @bb0185; @bb0040; @bb0190; @bb0155]), raised serum inflammatory markers during pregnancy ([@bb0060; @bb0045]), and childhood infection ([@bb0210; @bb0075; @bb0150]) have been reported to be associated with the increased risk of schizophrenia in adult life. Studies of individuals with first episode psychosis or acute psychotic relapse suggest an increase in proinflammatory cytokines in serum ([@bb0170]), a marker of activation of the innate immune response ([@bb0280]). A recent meta-analysis has reported increased serum C-reactive protein (CRP) in schizophrenia ([@bb0175]). However, longitudinal studies of circulating markers of inflammation in childhood and subsequent risk of psychotic outcomes are lacking.

Increased autoantibodies against various brain regions and ion channels have been reported in adult psychotic illness ([@bb0215; @bb0300]), a marker of activation of the adaptive immune response. Epidemiological studies have also reported increased prevalence of autoimmune conditions in schizophrenia, and family members of patients with schizophrenia ([@bb0095; @bb0065]). Adaptive immune response elicited by non-infectious antigens underlies atopic disorders such as asthma, atopic dermatitis, urticaria and allergic rhinitis ([@bb0130]). Therefore, it has been suggested that examination of possible links between immune responses and the development of schizophrenia should include atopic conditions as possible contributing factors ([@bb0220]). The evidence base on this subject is growing. So far, two cross-sectional studies have reported increased prevalence of asthma in schizophrenia ([@bb0070; @bb0275]). Recently, a large population-based longitudinal study has reported increased risk of adult schizophrenia in individuals with atopic disorders (asthma, atopic dermatitis, urticaria and allergic rhinitis) earlier in life ([@bb0200]). Effects of inflammatory response on the developing brain have been proposed as one mechanism that may underlie this association ([@bb0200]); also, other epidemiological observations of associations between early life infection and adult schizophrenia ([@bb0040; @bb0150; @bb0155]). However, empirical data on this topic involving human subjects is limited ([@bb0060; @bb0045]).

Population-based birth cohort studies have reported increased risk of adult psychotic illness among individuals reporting psychotic experiences (PEs) during childhood and adolescence ([@bb0205; @bb0290]). Early-life PEs also have been linked with a number of risk factors for schizophrenia ([@bb0120; @bb0255; @bb0295]). Therefore, it has been suggested that studies of early-life PEs may be helpful to elucidate the pathophysiology of adult psychotic disorders ([@bb0145; @bb0195]).

Using data from the population-based Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort, we report associations between early-life atopic disorders, serum inflammatory markers (interleukin 6 or IL-6 and CRP) at age 9 years, and the risk of PEs at age 13 years. We predicted that atopic disorders will be associated with both increased levels of inflammatory markers and the risk of PEs. We also predicted that inflammatory markers will be associated with the risk of PEs, and finally, that they will mediate the association between atopic disorders and PEs. [Fig. 1](#f0005){ref-type="fig"} illustrates the timing of data collection and the hypotheses tested.

2. Method {#s0010}
=========

2.1. Sample {#s0015}
-----------

The ALSPAC birth cohort is based on all pregnant women residing in the county of Avon, a geographically defined region in the southwest of England, with expected dates of delivery between April 1991 and December 1992 ([www.alspac.bris.ac.uk](http://www.alspac.bris.ac.uk){#ir0015}). The initial ALSPAC cohort consisted of 14,062 live births and 13,988 infants still alive at 12 months ([@bb0105; @bb0030]). Avon included both urban and rural areas, and the population was broadly representative of all children in the UK. The parents completed regular postal questionnaires about all aspects of their child\'s health and development since birth. Since the age of 7 years the children attended an annual assessment clinic during which they participated in a range of face-to-face interviews and physical tests. The current study is based on 6784 individuals who completed the Psychosis-like Symptoms interview (PLIKSi) at age 13 years.

Ethical approval for the study was obtained from ALSPAC Ethics and Law Committee and the Local Research Ethics Committees.

2.2. Assessment of psychotic experiences (PEs) {#s0020}
----------------------------------------------

Psychotic experiences were assessed by the semi-structured Psychosis-like Symptoms interview (PLIKSi) at a mean age of 12.9 years (SD = 0.23). The interview instrument comprised 12 'core' questions derived from the Diagnostic Interview Schedule for Children--IV (DISC--IV) ([@bb0235]), and the Schedules for Clinical Assessment in Neuropsychiatry version 2.0 (SCAN 2.0) ([@bb0285]). It included twelve key symptoms covering the three main domains of positive psychotic symptoms: hallucinations (visual and auditory); delusions (delusions of being spied on, persecution, thoughts being read, reference, control, grandiose ability, and other unspecified delusions); and bizarre symptoms (thought broadcasting, insertion and withdrawal). Interviewees were asked about the presence of these symptoms and frequency of symptoms. We used the observer based rating for the presence or absence of any psychotic experiences in the past six months as the main outcome (i.e. a binary dependent variable). We also examined twelve specific PEs individually as outcomes. The group with PEs was compared with the rest of the cohort. We chose the binary definition of outcome rather than a dimensional approach based on symptom frequency in order to maximize power in multivariable regression analysis.

The interviews were carried out by 13 psychology graduates who were trained by two experienced clinicians and SCAN trainers (a child psychiatrist and a general adult psychiatrist) ([@bb0120]). The interviewers were required to reach 95% agreement whilst scoring two 'gold standard' interview videotapes that were prepared by the trainers. Monthly booster training sessions and workshops were arranged to discuss scoring of complex cases and consolidate training. All interviews were audiotaped for each interviewer until they reached eight interviews containing several items rated 'positive' (i.e. PEs present). These tapes were independently rated by a second interviewer. The average inter-rater reliability for PLIKS interviews was good (kappa = 0.7) ([@bb0120]). Parents were not interviewed.

2.3. Assessment of atopic disorders {#s0025}
-----------------------------------

When ALSPAC participants were 10 years old their parents completed a postal questionnaire on various aspects of health and development of the child. This included questions on atopic conditions. Parents were asked whether anytime in the past a doctor had stated that the child suffered from asthma or eczema (original question: "*Has a doctor ever actually said that your study child has asthma or eczema?*"). Based on response to this question a single categorical exposure (or independent) variable was created, which included four groups: no asthma or eczema (reference group); only asthma; only eczema; both asthma and eczema.

2.4. Assays for inflammatory markers {#s0030}
------------------------------------

IL-6, a proinflammatory cytokine, and CRP, an acute phase protein, were measured in blood samples collected at age 9 years. Non-fasting blood samples were taken using standard procedures, with samples immediately spun and frozen at − 80 °C. The measurements were assayed in 2008 after a median of 7.5 years in storage with no previous freeze--thaw cycles during this period (n = 5076). IL-6 was measured by enzyme-linked immunosorbent assay (ELISA) (R&D systems, Abingdon, UK). CRP was measured by automated particle-enhanced immunoturbidimetric assay (Roche UK, Welwyn Garden City, UK). All assay coefficients of variation were \< 5% ([@bb0100]).

Acute infection is likely to cause a transient increase in serum IL-6 and CRP levels. Since we were interested in inflammatory markers in individuals with atopic disorders in healthy state, those who reported to have an infection at the time of blood collection or in the preceding week were excluded (n = 482). The information regarding infection was gathered in the clinic during blood collection using a questionnaire.

IL-6, IL-1β and tumour necrosis factor α (TNF-α) are important cytokines secreted by dendritic cells and macrophages following infection ([@bb0130]). These have a wide spectrum of biological effects that help to coordinate the body\'s response to infection including induction of acute phase proteins, raising body temperature ([@bb0130]). However, in other circumstances IL-6 also shows anti-inflammatory activities ([@bb0230]), which are consistent with the pleiotropic nature of most cytokines ([@bb0130]). In ALSPAC, apart from IL-6 and CRP no other inflammatory markers were assayed at age 9 years.

2.5. Assessment of covariates {#s0035}
-----------------------------

Age at the time of assessment of PEs (in weeks) and gender were associated with atopic disorder ([Table 1](#t0005){ref-type="table"}); these were included as potential confounders. We also included paternal social class and ethnicity, common correlates of psychotic outcomes as potential confounders. As per the UK Office of National Statistics (ONS) classification system paternal social class was recorded in six categories (I, II, III non-manual, III manual, IV, and V), in descending order, with professionals and higher managerial workers representing social class I ([@bb0005]). In addition, ALSPAC recorded a separate category for fathers working for the armed forces (0.3% of the entire cohort). However, this category is likely to represent different ONS social groups, and we did not have sufficient information to reassign these individuals to the original ONS categories. Therefore, the armed forces category was excluded from all analysis.

2.6. Statistical analysis {#s0040}
-------------------------

### 2.6.1. Atopic disorders and PEs {#s0045}

We used atopic disorders as the exposure/independent variable (categorical) and PEs as the outcome/dependent variable (binary). Multinomial logistic regression was used to calculate odds ratios for developing PEs in the following groups: asthma only; eczema only; both asthma and eczema. Those with no asthma or eczema were used as the reference group. Regression models were adjusted for age at the time of assessment of PEs, gender, social class and ethnicity. We also calculated the odds ratios for twelve specific PEs individually using the same procedure.

### 2.6.2. Atopic disorders and inflammatory markers {#s0050}

The relationship between atopy and inflammatory markers was examined using linear regression. IL-6 and CRP values were not normally distributed. Normality of distributions was achieved after natural logarithmic transformation. Log transformed values of IL-6 and CRP were used as the dependent variables. Regression models were adjusted for age at the time of blood test, gender, body mass index (BMI), social class and ethnicity, as these were associated with IL-6 (all p \< 0.05).

### 2.6.3. Inflammatory markers and PEs {#s0055}

Median and interquartile range of the observed values of IL-6 and CRP in those with PEs and the rest of the cohort have been presented. Using log transformed values of IL-6 and CRP (standardized) as the independent variable, we carried out binary logistic regression to calculate the odds ratios for PEs. Thus, the odds ratios represent the increase in the risk of PEs at age 13 years for each standard deviation increase in serum levels of inflammatory markers at age 9 years.

### 2.6.4. Mediation analysis {#s0060}

Any mediating effects of IL-6 or CRP on the association between atopy and PEs were examined using the following procedure ([@bb0135; @bb0015]). First, separate regression models assessed the associations between: (1) exposure (atopy) and outcome (PEs); (2) exposure and mediator (IL-6); (3) mediator and outcome controlling for exposure. If all of these associations were statistically significant, we proceeded to mediation analysis, whereby exposure--outcome, exposure--mediator, mediator--outcome, all three regression lines were fitted simultaneously in a single model using MPlus. It was expected that in the final step, the exposure--outcome relationship would be attenuated (partial mediation), or eliminated (complete mediation). In case of partial mediation, the extent to which the exposure--outcome estimate was attenuated after inclusion of the mediator was also calculated. This procedure was repeated using CRP as the potential mediator.

3. Results {#s0065}
==========

3.1. Baseline characteristics {#s0070}
-----------------------------

Data on atopic disorders stated by a doctor to be present in the child any time since birth until age 10 years were available for 7814 children. On whole, atopic disorders were more common in boys than girls. Baseline characteristics of individuals with and without atopic disorders have been presented in [Table 1](#t0005){ref-type="table"}.

3.2. Atopic disorders and the risk of psychotic experiences at age 13 years {#s0075}
---------------------------------------------------------------------------

[Fig. 2](#f0010){ref-type="fig"} presents total percentage of individuals with psychotic experiences (PEs) at age 13 years in different groups of atopic disorder at age 10 years.

Compared with those with no atopic disorder there was significant increase in risk of psychotic experiences at age 13 years among individuals with a history of atopic disorder ([Table 2](#t0010){ref-type="table"}). Adjustment for age, gender, social class and ethnicity had minimal influence on the odds ratios. With regards to specific PEs, asthma and eczema were associated with the risk of auditory hallucinations. The frequency of individual PEs and their association with atopic disorders have been presented in [Table 3](#t0015){ref-type="table"}.

3.3. Association between atopy and inflammatory markers {#s0080}
-------------------------------------------------------

Data on both atopy and inflammatory markers were available for about 3850 individuals after excluding those with an infection at the time of blood collection. Atopy was associated with increased serum IL-6 (β = 0.051; SE = 0.014; p \< 0.0001). The association was attenuated after adjusting for age, BMI, gender, social class and ethnicity but still remained statistically significant (β = 0.036; SE = 0.015; p = 0.01). Similar findings were observed for serum CRP (unadjusted β = 0.068; SE = 0.019; p \< 0.001; adjusted β = 0.039; SE = 0.019; p = 0.03).

3.4. Association between inflammatory markers and psychotic experiences {#s0085}
-----------------------------------------------------------------------

Data on inflammatory markers at age 9 years (after excluding those with infection) and psychotic experiences at age 13 years were available for 3747 individuals. Out of these, 498 had PEs (13.29%). Medians (interquartile range) of IL-6 for those with PEs and the rest of the cohort were 0.78 (0.47--1.36), and 0.75 (0.47--1.33) pg/ml. Medians (interquartile range) of CRP for those with PEs and the rest of the cohort were 0.22 (0.11--0.45), and 0.20 (0.11--0.47) mg/l.

Logistic regression showed that serum IL-6 and CRP levels were not associated with the risk of psychotic experiences. For each standard deviation increase in IL-6 the odds ratio for PEs was 0.98 (95% CI 0.90--1.08); p = 0.75. A similar result was observed for CRP; OR 1.03 (95% CI 0.93--1.14); p = 0.53.

3.5. Effect of inflammatory markers on the association between atopy and PEs {#s0095}
----------------------------------------------------------------------------

We examined whether the association between atopy (the group with both asthma and eczema) and PEs was mediated by serum IL-6. Step by step analysis showed that: (1) exposure (atopy) was associated with the outcome (PEs) (β = 0.368, SE = 0.14; p = 0.009); (2) exposure (atopy) was associated with the mediator (IL-6) (β = 0.156, SE = 0.05; p = 0.003); but (3) the mediator (IL-6) was not associated with the outcome (PEs) after controlling for the exposure (atopy) (β = 0.034, SE = 0.06; p = 0.61). Therefore, mediation analysis was not attempted (where the exposure--outcome, exposure--mediator, mediator--outcome all three regression lines would have been fitted simultaneously in a single model). However, in step three which included both IL-6 and atopy as predictors of PEs, an attenuation of the effect estimate between atopy and PEs was observed (β = 0.338, SE = 0.18; p = 0.06), compared with that in step one. This equated to only a 3% reduction of the atopy--PEs effect estimate by IL-6. Together, these results indicated that in our sample IL-6 neither mediated nor greatly confounded the association between atopy and PEs. Similar results were observed for CRP.

4. Discussion {#s0090}
=============

Our findings demonstrate that childhood atopic disorders are associated with the risk of developing psychotic experiences in adolescence. Compared to children with no atopic disorder in the first ten years of life, an increased risk of PEs at age 13 years has been observed in all groups with atopy (asthma, eczema, both). These associations are independent of effects of age at the time of assessment of PEs, gender, social class and ethnicity. To our knowledge, this is the first population-based longitudinal study of childhood atopic disorders and psychotic experiences in adolescence. These results are in line with previous reports of high comorbidity of asthma in adult schizophrenia ([@bb0070; @bb0275]), and higher risk of developing schizophrenia on follow-up among individuals with a history of atopic conditions (asthma, atopic dermatitis, urticaria and allergic rhinitis) ([@bb0200]).

An important methodological difference between our study and the previous studies of atopic disorders and psychosis needs to be acknowledged. The outcome of our study was psychotic experiences in early adolescence rather than diagnosis of schizophrenia. However, several lines of evidence suggest that early-life psychotic experiences may provide a valid paradigm for studying the development of adult psychotic disorders ([@bb0145; @bb0195]). First, prospective birth cohort studies suggest higher risk of psychotic disorders in adult life among individuals reporting psychotic symptoms in childhood ([@bb0205; @bb0290]). Second, childhood psychotic symptoms are associated with a number of risk factors for schizophrenia, such as prenatal maternal infection and obstetric complications ([@bb0295]), low birth weight ([@bb0255]), and poorer childhood IQ ([@bb0120]). Increased prevalence of antibodies to Epstein Barr Virus has been reported in adolescents reporting psychotic experiences ([@bb0270]) and in adult schizophrenia ([@bb0090]). A recent study from the ALSPAC birth cohort has reported increased risk of psychotic experiences in adolescence for autistic traits in early childhood ([@bb0020]). Together, these findings indicate that childhood psychotic experiences may have a developmental component to their origin. Third, population-based studies suggest psychotic symptoms in the general population and that observed in psychotic disorders may exist in a continuum ([@bb0265]). Finally, neurophysiological studies suggest common underlying mechanisms for psychotic symptoms seen in healthy people and in schizophrenia ([@bb0125]).

One explanation for the association between atopy and PEs could be the effect of medication. Individuals with asthma or treatment resistant eczema are sometimes prescribed oral steroids, which are also associated with the risk of psychosis. We did not have the data on steroid prescriptions. Thus the possibility of steroid medication as a mediator of the association between atopy and PEs cannot be ruled out.

Limitations of this study include the use of parent reported data rather than confirmatory tests for asthma or eczema. However, the questionnaire asked whether these conditions had been diagnosed by a doctor. Using a similar question (Have you ever had asthma?) the prevalence of asthma has been reported to be about 10% in 6--7 year old children in the Western Europe including UK ([@bb0160]), and about 20% in 12--14 year old children in the UK ([@bb0140]). These are comparable to the prevalence of parent-reported asthma in our sample (14.4% at age 10 years). Both atopy and PEs were assessed prospectively; thus, eliminating any chance of recall bias.

Degradation of inflammatory markers over time is possible. However, serum samples were frozen at − 80 °C, which is recommended as the optimum temperature for storage of these samples for cytokine assays at a later stage ([@bb0115; @bb0080]). There was no evidence of prior freeze--thaw cycles. Cytokine levels in blood samples collected at a non-fasting state could be affected by diurnal effect ([@bb0080]). However, the use of non-fasting samples would increase measurement error likely to be random in relation to outcome. We acknowledge that inflammatory markers were measured at age 9 years, and data on atopy were collected slightly later at age 10 years ([Fig. 1](#f0005){ref-type="fig"}). However, this is justified as the questionnaire asked about the diagnosis of atopy anytime in the past since birth, and atopy is considered as a long-term attribute in many individuals ([@bb0025]). The approach is also consistent with our hypothesis and the direction of association, i.e. atopy leads to increased IL-6/CRP.

To our knowledge, this is the first longitudinal study of childhood inflammatory markers and subsequent risk of psychotic outcomes. Meta-analyses have reported increased levels of inflammatory markers including IL-6 and CRP in schizophrenia ([@bb0170; @bb0175]). However, due to their cross sectional design these studies cannot establish whether increased inflammatory markers is a cause or consequence of the illness. We found no association between IL-6/CRP at age 9 years and risk of PEs at age 13 years. This could be due to a number of reasons. Measurement error as a result of non-fasting serum samples would contribute to the null finding. A previous meta-analysis suggests that IL-6 may be a state marker of acute psychosis ([@bb0170]). Since IL-6 is the primary inducer of CRP, the latter might also be a state marker. Thus, measurement of IL-6 and CRP several years before the assessment of PEs might explain why we did not observe an association between inflammatory markers and PEs. The same meta-analysis reported that other cytokines, including sIL-2R, IL-12, and TNF-α, appeared to be trait markers for schizophrenia ([@bb0170]). However, these cytokines were not included when the serum samples were analysed a few years ago in ALSPAC. In the future, studies should include a more comprehensive panel of inflammatory markers including cytokines and white blood cells measured over a period of time.

Effect of inflammatory cytokines on the developing brain has been proposed as a possible mechanism underlying the association between schizophrenia and early life infection. Birth cohort studies suggest that inflammatory cytokines (TNF-α) or chemokines (IL-8) may mediate the risk of schizophrenia in adult offspring associated with prenatal maternal infection ([@bb0060; @bb0045]). A possible role of inflammation in the pathogenesis of psychosis is also supported by animal studies. Simulated viral or bacterial infection or direct injection with the inflammatory cytokine IL-6 in pregnant mice has been reported to produce intermediate phenotypes related to schizophrenia in the adult offspring ([@bb0165]). Some of these phenotypes, such as deficits in sensory gating and abnormal latent inhibition are reversible by the antipsychotic clozapine ([@bb0245]). However, in our sample there was no indication that inflammatory markers explained the association between atopy and PEs. This could be related to the outcome studied. Adolescent participants with PEs in our sample are almost certainly a heterogeneous group. In many cases these symptoms are likely to be part of normal development, whilst in some they may be more pathological ([@bb0085; @bb0225]). Thus, any underlying biological effect (such as mediation by inflammatory markers) may have become diluted. Nevertheless, we found that atopic disorders were associated with higher levels of inflammatory markers and increased risk of PEs. Follow-up of these individuals will be useful to explore further the effect of atopy and inflammation on different developmental trajectories of early-life PEs.

Possible explanations for the observed association between atopy and psychotic experiences include an overlap of genetic risk between atopy and psychosis. For example, shared genetic susceptibility for schizophrenia and asthma has been proposed ([@bb0110; @bb0180; @bb0010]). Recent genome wide association studies have reported significant associations between schizophrenia and several markers spanning the major histocompatibility complex region on chromosome 6p21.3--22.1. This is consistent with an immune component to schizophrenia risk ([@bb0240; @bb0250]). Thus, it is possible that atopic conditions, in the presence of pre-existing genetic liability, can lead to a distinct or pathological immune response. In turn, this may lead to CNS alterations making these individuals susceptible to developing psychotic illness in adult life. In the future, prospective epidemiological studies with genetic and immunological data as well as detailed phenotypic characterisation during childhood and adult life are required to test this hypothesis. Animal models will be useful to identify specific mechanisms underlying behavioural and cognitive phenotypes relevant to schizophrenia involving genes and immunity.
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###### 

Baseline characteristics of individuals with and without atopic disorders.

  Groups/characteristics                                     Asthma         Eczema         Both asthma and eczema   No atopy       p value[a](#tf0005){ref-type="table-fn"}
  ---------------------------------------------------------- -------------- -------------- ------------------------ -------------- ------------------------------------------
  n (%)                                                      1125 (14.4%)   994 (12.7%)    574 (7.3%)               5121 (65.5%)   
  Age at the time of assessment of PEs, mean (SD) in years   12.87 (0.24)   12.86 (0.20)   12.84 (0.19)             12.87 (0.21)   0.02
  Male (%)                                                   58.8           44.2           54.2                     49.5           \< 0.001
  British White (%)                                          98.3           97.7           98.1                     98.4           0.75
  Social class (%)                                                                                                                 0.14
   I                                                         11.9           14.7           11.2                     13.3           
   II                                                        33.3           35.4           39.4                     36.5           
   III non-manual                                            11.5           12.4           12.2                     12.2           
   III manual                                                30.7           28.0           28.0                     27.8           
   IV                                                        10.4           7.2            7.7                      7.7            
   V                                                         2.2            2.3            1.5                      2.5            

Chi-square test, except mean age, which is independent sample *T*-test.

###### 

Atopic disorders and risk of psychotic experiences at age 13 years in ALSPAC cohort.

  Exposure/independent variable (atopy)[a](#tf0010){ref-type="table-fn"}   Adjustment for confounding   n                   Odds ratio (95% CI) for the outcome/dependent variable (PEs)
  ------------------------------------------------------------------------ ---------------------------- ------------------- --------------------------------------------------------------
  Eczema                                                                   Unadjusted                   5727                1.26 (1.00--1.58)
  Adjusted[b](#tf0015){ref-type="table-fn"}                                4923                         1.33 (1.04--1.69)   
  Asthma                                                                   Unadjusted                   5727                1.35 (1.09--1.86)
  Adjusted                                                                 4923                         1.37 (1.08--1.74)   
  Both asthma and eczema                                                   Unadjusted                   5727                1.45 (1.10--1.90)
  Adjusted                                                                 4923                         1.44 (1.07--1.95)   

The group with no atopic disorders (i.e. no asthma or eczema) was used as reference (odds ratio = 1).

Adjusted for age at the time of assessment of PEs, gender, social class and ethnicity.

###### 

Associations between atopic disorders and specific psychotic experiences in ALSPAC cohort.

  Psychotic experiences (PEs)       Sample (% of PEs)   Odds ratio (95% CI) for PEs in groups of atopic disorder                       
  --------------------------------- ------------------- ---------------------------------------------------------- ------------------- --------------------
  Auditory hallucinations           5722 (6.8)          1.60 (1.21--1.99)                                          1.49 (1.11--1.99)   1.35 (0.93--1.97)
  Visual hallucinations             5728 (2.4)          1.20 (0.74--1.96)                                          1.39 (0.87--2.22)   1.16 (0.61--2.20)
  Delusions of being spied on       5723 (2.7)          1.05 (0.65--1.68)                                          1.00 (0.61--1.63)   1.33 (0.76--2.31)
  Delusions of persecution          5723 (0.2)          0.46 (0.06--3.61)                                          0.48 (0.06--3.97)   0.85 (0.11--6.65)
  Delusions of thought being read   5729 (0.6)          1.01 (0.38--2.66)                                          0.84 (0.29--2.44)   1.11 (0.33--3.72)
  Delusions of reference            5729 (0.7)          0.85 (0.33--2.23)                                          0.72 (0.25--2.05)   0.94 (0.28--3.13)
  Delusions of control              5728 (0.6)          1.01 (0.38--2.65)                                          0.84 (0.30--2.44)   1.86 (0.70--4.92)
  Delusions of grandiose ability    5729 (1.1)          0.51 (0.20--1.30)                                          0.75 (0.34--1.67)   1.33 (0.60--2.97)
  Other delusions                   5727 (0.4)          0.38 (0.05--2.96)                                          1.21 (0.34--4.31)   3.57 (1.25--10.20)
  Thought broadcasting              5725 (1.3)          1.51 (0.80--2.84)                                          1.84 (1.01--3.34)   1.50 (0.66--3.36)
  Thought insertion                 5729 (1.3)          1.21 (0.64--2.30)                                          0.95 (0.46--1.94)   0.92 (0.36--2.34)
  Thought withdrawal                5727 (0.3)          0.61 (0.14--2.70)                                          0.64 (0.18--2.83)   0.56 (0.07--4.31)
